Skip to main content

Congratulations to the Anaveon team on their CHF 110 Million Series B round!

Andreas Katopodis, Co-founder and CEO of Anaveon (Image: Jasmin Rei)

Back in 2017, when we first met Andreas Katopodis, he had the vision to build a company that translates breakthrough science in the field of cytokine biology, exploiting the power of engineered cytokines to develop safe and effective treatments for serious diseases. Now, this vision is coming quickly to fruition with Anaveon undertaking a Phase I/II study to evaluate its lead program, ANV419, a powerful and selective interleukin-2 agonist in patients with solid tumors, bringing it closer to the patients who need them!

For us, it was a pleasure to support Andreas Katopodis, co-founder and CEO, and the rest of the team to help them build the company from scratch, upon their expertise in immune-mediated diseases, and to watch this company grow! We cannot wait to see what the future has in store!

Read their press release on their recent CHF 110 Million Series B here, one of the largest follow-on funding rounds in Switzerland ever.

Want to find more about Anaveon? Read their success story as a BaseLaunch Portfolio company here.

Share this article

View all news

Sign up to receive our newsletter in your inbox.